Takeda reports cancer trial gains as Takeda Pharmaceutical stock trades at EUR 18.00
Published on 10/24/2026 at 10:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCancer data and trading dates
- Takeda announced positive Phase 3 cancer-study results on October 23, 2026.
- Takeda Pharmaceutical stock traded at EUR 18.00 in weekend trading at 10:21 a.m. CEST on October 24, 2026.
- The next Xetra session is scheduled for October 26, 2026.
Takeda announced positive Phase 3 cancer-study results on October 23, 2026, according to the company release. Takeda Pharmaceutical stock traded at EUR 18.00 in weekend trading at 10:21 a.m. CEST on October 24, 2026, according to Lang & Schwarz.
Market context: Market report Nikkei 225.
The week in figures
Lang & Schwarz quoted Takeda at EUR 18.00 at 10:21 a.m. CEST on October 24, 2026. The quote was in weekend trading, while Xetra was closed.
The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.
Chronology of the week
On October 23, Takeda said arcotatug tavatecan met the dual primary endpoints of overall survival and progression-free survival in the Phase 3 G-HOPE-001 study. The company reported median overall survival of 10.2 months with arcotatug tavatecan versus 6.9 months with treatment of physician’s choice, and median progression-free survival of 7.1 months versus 3.1 months. The results were presented at the 2026 European Society for Medical Oncology Congress, according to the Takeda release.
On October 15, Takeda announced that ORZEYFUL, or oveporexton, was available in Japan and China for the treatment of narcolepsy type 1. The company described the medicine as an oral orexin receptor 2 agonist, according to a company release.
Dates of the coming week
The next Xetra session is scheduled for October 26, 2026. Takeda’s release dated October 23 said the arcotatug tavatecan data will support a planned regulatory filing in Japan, while the compound remains investigational and has not been approved by regulatory authorities.
